HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

MD

Pediatrix Medical Group, Inc. (NYSE)

Healthcare — Medical Care Facilities

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

Buy 2.4 / 5 6 analysts
$25.72
$-0.42 (-1.61%)
Target: $23.17 (-9.9%)
Sign in to add MD to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$2.15B
P/E Ratio (TTM)12.69
Forward P/E11.08
EPS (TTM)$2.06
Dividend Yield-
Profit Margin9.02%
Revenue Growth3.90%
ROE20.89%
Debt/Equity71.68
Recommendation Buy 2.4
Analyst Target$23.17
Analysts6
Indexes NYSE

Technical Indicators

RSI (14)77.9
Beta0.70
SMA 20-
SMA 40-
52-Week High$26.44
52-Week Low$11.84
50-Day Avg$23.04
200-Day Avg$21.07
Avg Volume845.5K
Volume284.2K

Performance Analysis

NEUTRAL

MD presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($26.44), which may indicate limited upside.
- RSI at 77.9 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ P/E of 12.7 suggests the stock may be undervalued.
~ Modest revenue growth of 3.9% year-over-year.
+ Wall Street consensus is "Buy" from 6 analysts.
- Average analyst target of $23.17 implies 9.9% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:19 UTC

Back to Screener Export Report